Special Issue "Pathology, Diagnosis and Treatment in Non-small Cell Lung Cancer"
Deadline for manuscript submissions: 12 April 2024 | Viewed by 130
Lung cancer is the leading cause of cancer death worldwide. Over the past decade, significant improvements in overall survival were observed in patients with non-small cell lung cancer. A backbone for improving prognosis are advanced diagnostic and treatment techniques. Today, non-small lung cancer is a heterogenous disease. Critical to the management of this cancer is a proper pathological diagnosis, including the phenotyping of tumor cells. All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations before therapy for advanced lung cancer is implemented. Approximately 30-50% of patients with lung cancer tumors have potentially curable driver alterations. A group of patients without a driven mutation can be treated with immunotherapy. PDL1 expression has many limitations as a biomarker. The establishment of a well-defined universal predictive biomarker for immunotherapy is an unmet need. This Special Issue aims to review the advances in pathology, molecular diagnosis and treatment techniques in non-small cell lung cancer.
Dr. Adam Płużański
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- non-small cell lung cancer
- molecular diagnosis